Characterisation of adiponectin multimers and the IGF axis in humans with a heterozygote mutation in the tyrosine kinase domain of the insulin receptor gene

European Journal of Endocrinology

Volumn 166, Issue 3, 2012, Pages 511-519

  Højlund, Kurt ^a   Beck Nielsen, Henning ^a   Flyvbjerg, Allan ^b   Frystyk, Jan ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; GLUCOSE; INSULIN; LEPTIN; PROTEIN TYROSINE KINASE; SOMATOMEDIN; SOMATOMEDIN A; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; HETEROZYGOTE; HUMAN; HYPERINSULINEMIA; INSULIN LIKE ACTIVITY; INSULIN RECEPTOR GENE; INSULIN RESISTANCE; MALE; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RECEPTOR GENE; SIGNAL TRANSDUCTION;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; FEMALE; HETEROZYGOTE DETECTION; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; RECEPTOR, INSULIN;

EID: 84857986053     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0790     Document Type: Article

References (46)

1. Galic S, Oakhill JS & Steinberg GR. Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology 2010 316 129-139. (doi:10.1016/j.mce.2009.08.018)
2. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Højlund K & Nolan JJ &European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group), Savage DB. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 2009 52 2345-2349. (doi:10.1007/s00125-009-1508-3)
3. Trujillo ME & Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine 2005 257 167-175. (doi:10.1111/j.1365-2796.2004.01426.x)
4. Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S,Williams CJ & Mantzoros CS. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007 30 280-285. (doi:10.2337/dc06-1362)
5. Cook JR & Semple RK. Hypoadiponectinemia - cause or consequence of human "insulin resistance"? Journal of Clinical Endocrinology and Metabolism 2010 95 1544-1554. (doi:10.1210/jc.2009-2286)
6. Behre CJ. Adiponectin and its role. Scandinavian Journal of Clinical & Laboratory Investigation 2008 68 678-680. (doi:10.1080/00365510802267077)
7. Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ & O'Rahilly S. Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism 2006 91 3219-3223. (doi:10.1210/jc.2006- 0166)
8. Semple RK, Halberg NH, Burling K, Soos MA, Schraw T, Luan J, Cochran EK, Dunger DB, Wareham NJ, Scherer PE, Gorden P &O'Rahilly S. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007 56 1712-1717. (doi:10.2337/db06-1665)
9. Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P & O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008 31 977-979. (doi:10.2337/dc07-2194)
10. Højlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF &Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006 49 1283-1291. (doi:10.1007/s00125-006- 0240-5)
11. Möhlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF & Spranger J. Insulin decreases human adiponectin plasma levels. Hormone and Metabolic Research 2002 34 655-658. (doi:10.1055/s-2002-38248)
12. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Parving HH & Flyvbjerg A. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 2008 93 3186-3191. (doi:10.1210/jc.2008-0360)
13. McDonald A, Williams RM, Regan FM, Semple RK & Dunger DB. IGF-I treatment of insulin resistance. European Journal of Endocrinology 2007 157 (Suppl 1) S51-S56. (doi:10.1530/EJE-07-0271)
14. Semple RK, Williams RM & Dunger DB. What is the best management strategy for patients with severe insulin resistance? Clinical Endocrinology 2010 73 286-290. (doi:10.1111/j.1365-2265.2010.03810.x)
15. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE & Strickler HD. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes/Metabolism Research and Reviews 2009 25 3-12. (doi:10.1002/dmrr.919)
16. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S & Ørskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews1999 15 314-322. (doi:10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.0. CO;2-E)
17. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone & IGF Research 2004 14 337-375. (doi:10.1016/j.ghir.2004.06.001)
18. Maddux BA, Chan A, De Filippis EA, Mandarino LJ & Goldfine ID. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 2006 29 1535-1537. (doi:10.2337/dc05-1367)
19. Arafat AM,Weickert MO, Frystyk J, Spranger J, Schöfl C, Möhlig M & Pfeiffer AF. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. Journal of Clinical Endocrinology and Metabolism 2009 94 5093-5101. (doi:10.1210/jc.2009- 0875)
20. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG &Gibson JM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology & Diabetes 2006 114 371-376. (doi:10.1055/s-2006-924320)
21. Ogilvy-Stuart AL, Soos MA, Hands SJ, Anthony MY, Dunger DB &O'Rahilly S. Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. Journal of Clinical Endocrinology and Metabolism 2001 86 3319-3326. (doi:10.1210/jc.86.7.3319)
22. Højlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O & Beck-Nielsen H. A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. Diabetes 2004 53 1592-1598. (doi:10.2337/diabetes.53.6.1592)
23. Højlund K, Wojtaszewski JF, Birk J, Hansen BF, Vestergaard H &Beck-Nielsen H. Partial rescue of in vivo insulin signalling in skeletal muscle by impaired insulin clearance in heterozygous carriers of a mutation in the insulin receptor gene. Diabetologia 2006 49 1827-1837. (doi:10.1007/s00125- 006-0312-6)
24. Frystyk J, Tarnow L, Krarup HT, Parving HH & Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005 48 1911-1918. (doi:10.1007/s00125-005-1850-z)
25. Andersen KK, Frystyk J, Wolthers OD, Heuck C & Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. Journal of Clinical Endocrinology and Metabolism 2007 92 1857-1862. (doi:10.1210/jc.2006-2310)
26. Asferg C, Møgelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, Appleyard M, Jensen GB & Jeppesen J. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. American Journal of Hypertension 2010 23 327-333. (doi:10.1038/ajh.2009.244)
27. Frystyk J, Dinesen B & Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulinlike growth factor I and II. Growth Regulation 1995 5 169-176.
28. Frystyk J, Skjærbæk C, Dinesen B & Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Letters 1994 348 185-191. (doi:10.1016/0014-5793(94)00602-4)
29. Westwood M, Gibson JM, Davies AJ, Young RJ & White A. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. Journal of Clinical Endocrinology and Metabolism 1994 79 1735-1741. (doi:10.1210/jc.79.6.1735)
30. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW & Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Journal of Clinical Endocrinology and Metabolism 2003 88 132-135. (doi:10.1210/jc.2002-021349)
31. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992 41 1473-1490. (doi:10.2337/diabetes.41.11.1473)
32. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T &Nakano Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006 55 1954-1960. (doi:10.2337/db05-1525)
33. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R & Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006 29 1357-1362. (doi:10.2337/dc05-1801)
34. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A &Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. Journal of Clinical Endocrinology and Metabolism 2006 91 3873-3877. (doi:10.1210/jc.2006- 1158)
35. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS & Hu FB. Total and high-molecularweight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Annals of Internal Medicine 2008 149 307-316.
36. Basu R, Pajvani UB, Rizza RA & Scherer PE. Selective down-regulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007 56 2174-2177. (doi:10.2337/db07-0185)
37. Murdolo G, Hammarstedt A, Schmelz M, Jansson PA & Smith U. Acute hyperinsulinemia differentially regulates interstitial and circulating adiponectin oligomeric pattern in lean and insulin-resistant, obese individuals. Journal of Clinical Endocrinology and Metabolism 2009 94 4508-4516. (doi:10.1210/jc.2009-0431)
38. Lara-Castro C, Luo N, Wallace P, Klein RL & Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006 55 249-259. (doi:10.2337/diabetes.55.01.06.db05-1105)
39. Schober F, Neumeier M, Weigert J, Wurm S, Wanninger J, Schäffler A, Dada A, Liebisch G, Schmitz G, Aslanidis C &Buechler C. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochemical and Biophysical Research Communications 2007 361 968-973. (doi:10.1016/j.bbrc.2007.07.106)
40. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M & Perticone F. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005 28 120-125. (doi:10.2337/diacare.28.1.120)
41. Ezzat VA, Duncan ER, Wheatcroft SB & Kearney MT. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism 2008 10 198-211. (doi:10.1111/j.1463-1326.2007.00709.x)
42. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB &Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745. (doi:10.1016/S0140-6736(02)08655-5)
43. Longo N, Singh R & Elsas LJ. Decreased half-life of insulin-like growth factor I in Rabson-Mendenhall syndrome. Journal of Inherited Metabolic Disease 2001 24 546-550. (doi:10.1023/A:1012411709972)
44. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS & Friedman JM. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metabolism 2010 11 11-22. (doi:10.1016/j.cmet.2009.11.007)
45. Kraus D, Herman MA & Kahn BB. Leveraging leptin for type I diabetes? PNAS 2010 107 4793-4794. (doi:10.1073/pnas.1000736107)
46. Claudio M, Benjamim F, Riccardo B, Massimiliano C, Francesco B &Luciano C. Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity 2010 18 2055-2057. (doi:10.1038/oby.2010.7)